X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs DR. REDDYS LAB - Comparison Results

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES DR. REDDYS LAB VENUS REMEDIES/
DR. REDDYS LAB
 
P/E (TTM) x -692.7 29.5 - View Chart
P/BV x 0.2 2.9 7.0% View Chart
Dividend Yield % 0.0 0.9 -  

Financials

 VENUS REMEDIES   DR. REDDYS LAB
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
DR. REDDYS LAB
Mar-17
VENUS REMEDIES/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs2183,397 6.4%   
Low Rs822,560 3.2%   
Sales per share (Unadj.) Rs365.6856.5 42.7%  
Earnings per share (Unadj.) Rs1.578.0 1.9%  
Cash flow per share (Unadj.) Rs37.9139.9 27.1%  
Dividends per share (Unadj.) Rs020.00 0.0%  
Dividend yield (eoy) %00.7 0.0%  
Book value per share (Unadj.) Rs382.5739.8 51.7%  
Shares outstanding (eoy) m11.44165.74 6.9%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x0.43.5 11.8%   
Avg P/E ratio x101.038.2 264.3%  
P/CF ratio (eoy) x4.021.3 18.6%  
Price / Book Value ratio x0.44.0 9.7%  
Dividend payout %025.7 0.0%   
Avg Mkt Cap Rs m1,717493,632 0.3%   
No. of employees `0001.022.7 4.5%   
Total wages/salary Rs m32431,068 1.0%   
Avg. sales/employee Rs Th4,100.76,259.0 65.5%   
Avg. wages/employee Rs Th318.01,369.8 23.2%   
Avg. net profit/employee Rs Th16.7569.7 2.9%   
INCOME DATA
Net Sales Rs m4,183141,961 2.9%  
Other income Rs m201,715 1.2%   
Total revenues Rs m4,203143,676 2.9%   
Gross profit Rs m81224,722 3.3%  
Depreciation Rs m41710,266 4.1%   
Interest Rs m380634 59.9%   
Profit before tax Rs m3515,537 0.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m0349 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m182,965 0.6%   
Profit after tax Rs m1712,921 0.1%  
Gross profit margin %19.417.4 111.4%  
Effective tax rate %51.619.1 270.2%   
Net profit margin %0.49.1 4.5%  
BALANCE SHEET DATA
Current assets Rs m2,77196,837 2.9%   
Current liabilities Rs m1,93184,199 2.3%   
Net working cap to sales %20.18.9 225.4%  
Current ratio x1.41.2 124.7%  
Inventory Days Days12573 170.5%  
Debtors Days Days5498 55.0%  
Net fixed assets Rs m5,328102,552 5.2%   
Share capital Rs m114829 13.8%   
"Free" reserves Rs m4,177121,792 3.4%   
Net worth Rs m4,376122,621 3.6%   
Long term debt Rs m1,9115,449 35.1%   
Total assets Rs m8,428218,165 3.9%  
Interest coverage x1.125.5 4.3%   
Debt to equity ratio x0.40 982.4%  
Sales to assets ratio x0.50.7 76.3%   
Return on assets %4.76.2 75.8%  
Return on equity %0.410.5 3.7%  
Return on capital %6.612.9 51.2%  
Exports to sales %054.6 0.0%   
Imports to sales %20.59.4 219.5%   
Exports (fob) Rs mNA77,520 0.0%   
Imports (cif) Rs m85813,274 6.5%   
Fx inflow Rs m081,670 0.0%   
Fx outflow Rs m85826,355 3.3%   
Net fx Rs m-85855,315 -1.6%   
CASH FLOW
From Operations Rs m46921,444 2.2%  
From Investments Rs m29-18,404 -0.2%  
From Financial Activity Rs m-464-3,692 12.6%  
Net Cashflow Rs m35-1,144 -3.0%  

Share Holding

Indian Promoters % 32.9 25.5 128.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 5.4 3.3%  
FIIs % 0.6 35.3 1.6%  
ADR/GDR % 0.0 18.5 -  
Free float % 66.4 15.3 434.0%  
Shareholders   20,121 75,885 26.5%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   ELDER PHARMA  FDC LTD.  SHASUN PHARMA  DISHMAN PHARMA  TTK HEALTHCARE  

Compare VENUS REMEDIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Lower; Energy & PSU Stocks Lose(09:30 am)

Asian stocks are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 1.67% while the Hang Seng is down 0.87%. The Nikkei 225 is trading down by 1.18%.

Related Views on News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Feb 22, 2018 10:25 AM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS